Contracts › W81XWH22C0045
W81XWH22C0045: Research and Development for Army Phase Ii Sbir Month 1-24 Project Titled, Developing an Ideal First Use Agent to Prevent Sepsis in Trauma Wounds During Care Under Fire
Awarded to Altrazeal Life Sciences Inc by Defense Health Agency.
$1.2Mobligated
$1.2Mpotential value
05 January 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | W81XWH22C0045 |
|---|---|
| Awardee | Altrazeal Life Sciences Inc |
| Awarding agency | Defense Health Agency |
| Awarding office | DEFENSE HEALTH AGENCY |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | TX |
| Offers received | 1 |
| Period of performance | 06 September 2022 to 05 January 2027 |
| Potential end | 05 January 2027 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record